H.R. 5027 · 118th Congress

Chronic Kidney Disease Improvement in Research and Treatment Act of 2023

Introduced on Jul 27, 2023 by Carol D. Miller (R-WV-1). 13 cosponsors, 11 of them from another party. Latest action (Dec 17, 2024): Referred to the Subcommittee on Health.

Stage
Introduced
Introduced
Jul 27, 2023
Cosponsors
13
11 from the other party
Policy area
Health
Open in the Congress explorerCongress.govAlert me

Progress

The furthest stage the measure reached. Simple and concurrent resolutions do not go to the President.

  1. Introduced
  2. 2Reported by committee
  3. 3Passed one chamber
  4. 4Passed both chambers
  5. 5Sent to the President
  6. 6Became law

Official title

To improve the understanding of, and promote access to treatment for, chronic kidney disease, and for other purposes.

Subjects

  • Advanced technology and technological innovations
  • Congressional oversight
  • Digestive and metabolic diseases
  • Drug therapy
  • Government studies and investigations
  • Health care coverage and access
  • Health personnel
  • Health promotion and preventive care
  • Health technology, devices, supplies
  • Higher education
  • Medical research
  • Medical tests and diagnostic methods
  • Medicare
  • National and community service
  • Prescription drugs
  • Student aid and college costs

Summary

The Congressional Research Service has not summarized this measure yet.

Sponsor and cosponsors

Cosponsors by party as of the day they signed on. Original cosponsors signed on the day of introduction.

Carol D. MillerR-WV-1Sponsor

Democrats · 11

Republicans · 2

Roll calls

Recorded votes on the measure. Most measures move by voice vote or unanimous consent, which record no individual positions.

No recorded roll call on this measure: it moved by voice vote or unanimous consent, or has not reached the floor.

History

Every action as published, oldest first. Roll calls link to how each member voted.

  1. Jul 27, 2023Introduced in House
  2. Jul 27, 2023Introduced in House
  3. Jul 27, 2023 · HouseReferred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  4. Jul 27, 2023 · HouseReferred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  5. Jul 28, 2023 · HouseReferred to the Subcommittee on Health.
  6. Dec 17, 2024 · HouseReferred to the Subcommittee on Health.

Committees

Committees and subcommittees the measure was referred to.

Agencies in its committees' jurisdiction

Analisa's mapping of committee jurisdiction to federal agencies; the bill may touch others, or none of these.

Who lobbied on it

Organizations whose lobbying reports (LD-2) name this measure. Spending is what they reported for those quarters on all issues, not on this measure alone.

  1. Fresenius Medical Care North America15 reports
    $8.3M reported (all issues)
  2. Kidney Care Partners10 reports
    $650K reported (all issues)
  3. American Kidney Fund5 reports
    $955K reported (all issues)
  4. American Nephrology Nurses Association5 reports
    $150K reported (all issues)
  5. Dialysis Patient Citizens5 reports
    $2M reported (all issues)
  6. The Rogosin Institute5 reports
    $150K reported (all issues)Federal contractor: THE ROGOSIN INSTITUTE INC$297.5K in contracts, FY2026AI match · 100%
  7. AKEBIA THERAPEUTICS INC.4 reports
    $1.2M reported (all issues)
  8. The Kidney Care Council4 reports
  9. CorMedix Inc.3 reports
    $540K reported (all issues)
  10. DAVITA INC.3 reports
    $3.2M reported (all issues)Federal contractor: DAVITA INC.$179.4M in contracts, FY2026AI match · 97%
  11. American Society of Nephrology2 reports
    $190K reported (all issues)Federal contractor: AMERICAN SOCIETY OF NEPHROLOGY INCAI match · 100%
  12. ARDELYX, INC.1 report
  13. Cara Therapeutics1 report

Reports filed in 2023, 2024.

Sources and method

Every figure on this page traces to these records.

  • Bill status: bills and resolutions, sponsors, actions, subjects and CRS summaries (U.S. Government Publishing Office (GovInfo), from Congress.gov (Library of Congress))GovInfo Bill Status bulk data (Congress.gov; summaries by the Congressional Research Service) · data current to Oct 9, 2026 · loaded Oct 9, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Members of Congress, their terms, committees and identifiers (The @unitedstates project (from the Biographical Directory of the U.S. Congress, the House and the Senate))unitedstates/congress-legislators: legislators, committees and current committee membership · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: CC0 1.0 (public domain dedication)
  • House roll-call votes (Office of the Clerk, U.S. House of Representatives)Office of the Clerk, U.S. House of Representatives, roll-call vote records · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Senate roll-call votes and DW-NOMINATE scores (Voteview (UCLA Department of Political Science))Lewis, Jeffrey B., Keith Poole, Howard Rosenthal, Adam Boche, Aaron Rudkin, and Luke Sonnet (2026). Voteview: Congressional Roll-Call Votes Database. https://voteview.com/ · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Free to use with the required citation
  • Lobbying disclosures (LD-1 registrations, LD-2 quarterly reports, LD-203 contribution reports) (Clerk of the U.S. House of Representatives)Clerk of the House, Lobbying Disclosure Act filings (organizations only; lobbyists' names are not loaded) · data current to Oct 9, 2026 · loaded Oct 9, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Positions are shown only where a roll call recorded them; voice votes and unanimous consent record none.
  • Money and votes are shown side by side; neither explains the other.